Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced the completion of the next generation of its flagship informatics platform. The Ehave Platform upgrade leverages the functionality found within the Ehave Platform Core and simplifies the hosting of third-party digital tools and applications for mental health, including the recently launched Conners® suite of assessments to diagnose attention deficit hyperactivity disorder (“ADHD”) offered digitally by Ehave in partnership with Multi-Health Systems (“MHS”). Ehave also announced the launch of Ehave Connect, a digital “App Store” designed to enhance access to a broad array of content offered by Ehave and its growing roster of mental healthcare partners.
The Ehave Platform’s flexibility allows new content to be added quickly, and supports creation of third-party content by allowing developers access to its library of clinical protocols, which includes proven cognitive assessments that can be easily embedded into new applications and digital games designed to improve the diagnosis and/or treatment of mental health conditions.
Developers and organizations that partner with Ehave to commercialize or utilize content through the Ehave Platform will benefit from Ehave’s unprecedented back-end data management software, which is designed to offer a comprehensive view of a patient’s mental healthcare journey. The system upgrade enables organizations to register individual users and modulate workflows to best suit the needs of clinicians and researchers. Ehave Connect currently offers a variety of assessment tools, including Ehave’s proprietary MegaTeam applications.
Prateek Dwivedi, CEO of Ehave, said “The release of this upgraded version of the Ehave Platform signals that we are moving into the next chapter for Ehave. I was recruited to Ehave with the vision to mold the Ehave Platform into an all-encompassing mental healthcare informatics solution, providing physicians and researchers both trusted and novel tools to enhance the lives of their patients. Ehave Connect provides a nimble and adaptable platform for strategic partners to seamlessly integrate content and manage data, and is a critical step towards our vision of enabling objective, data-driven decisions for mental healthcare providers from patient intake through patient outcomes verification.”
Further expansion is planned for Ehave’s partnership with MHS to offer digital versions of its entire catalogue of clinically validated mental health assessments through Ehave Connect. Integration is currently underway for MHS’s Davidson Trauma Scale™ post-traumatic stress disorder (“PTSD”) assessment suite to enable Ehave to administer an upcoming clinical trial in partnership with MedReleaf, which will evaluate the potential of medical cannabis in the treatment of patients suffering from PTSD. The Ehave Platform-powered MedReleaf branded app is designed to empower physicians and researchers with the ability to track medication adherence and patient outcomes for various cannabis-based therapeutics and dosing regimens.
Ehave (Ticker: EHVVF) is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. Ehave’s mental health informatics platform facilitates objective, data-driven decision making while keeping patients informed and engaged throughout their mental healthcare journey. Ehave offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf (TSE: LEAF).
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.